MSFT   212.83 (-0.70%)
NVDA   419.46 (-0.21%)
CGC   16.85 (+5.18%)
BABA   261.03 (-0.21%)
GE   6.65 (+1.06%)
T   29.92 (+1.29%)
ACB   11.90 (+1.10%)
GILD   76.18 (+1.97%)
DIS   118.96 (+1.83%)
NFLX   540.46 (+6.44%)
BA   176.78 (+2.02%)
MSFT   212.83 (-0.70%)
NVDA   419.46 (-0.21%)
CGC   16.85 (+5.18%)
BABA   261.03 (-0.21%)
GE   6.65 (+1.06%)
T   29.92 (+1.29%)
ACB   11.90 (+1.10%)
GILD   76.18 (+1.97%)
DIS   118.96 (+1.83%)
NFLX   540.46 (+6.44%)
BA   176.78 (+2.02%)
MSFT   212.83 (-0.70%)
NVDA   419.46 (-0.21%)
CGC   16.85 (+5.18%)
BABA   261.03 (-0.21%)
GE   6.65 (+1.06%)
T   29.92 (+1.29%)
ACB   11.90 (+1.10%)
GILD   76.18 (+1.97%)
DIS   118.96 (+1.83%)
NFLX   540.46 (+6.44%)
BA   176.78 (+2.02%)
MSFT   212.83 (-0.70%)
NVDA   419.46 (-0.21%)
CGC   16.85 (+5.18%)
BABA   261.03 (-0.21%)
GE   6.65 (+1.06%)
T   29.92 (+1.29%)
ACB   11.90 (+1.10%)
GILD   76.18 (+1.97%)
DIS   118.96 (+1.83%)
NFLX   540.46 (+6.44%)
BA   176.78 (+2.02%)
Log in

NASDAQ:EDITEditas Medicine Stock Price, Forecast & News

$33.14
-1.35 (-3.91 %)
(As of 07/10/2020 01:02 PM ET)
Add
Compare
Today's Range
$33.05
Now: $33.14
$34.91
50-Day Range
$25.01
MA: $29.26
$34.63
52-Week Range
$14.01
Now: $33.14
$36.78
Volume14,788 shs
Average Volume1.52 million shs
Market Capitalization$1.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.04
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Editas Medicine logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.53 million
Book Value$5.12 per share

Profitability

Net Income$-133,750,000.00
Net Margins-588.05%

Miscellaneous

Employees133
Market Cap$1.83 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

How has Editas Medicine's stock been impacted by COVID-19 (Coronavirus)?

Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EDIT shares have increased by 63.5% and is now trading at $33.14. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Editas Medicine?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Editas Medicine.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Editas Medicine.

How were Editas Medicine's earnings last quarter?

Editas Medicine Inc (NASDAQ:EDIT) issued its earnings results on Thursday, May, 7th. The company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.10. The firm had revenue of $5.70 million for the quarter, compared to analyst estimates of $6.73 million. Editas Medicine had a negative return on equity of 63.21% and a negative net margin of 588.05%. The firm's quarterly revenue was up 171.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.60) EPS. View Editas Medicine's earnings history.

What price target have analysts set for EDIT?

7 brokers have issued 12-month target prices for Editas Medicine's stock. Their forecasts range from $27.00 to $55.00. On average, they expect Editas Medicine's stock price to reach $39.20 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View analysts' price targets for Editas Medicine.

What are Wall Street analysts saying about Editas Medicine stock?

Here are some recent quotes from research analysts about Editas Medicine stock:
  • 1. According to Zacks Investment Research, "Editas’ earnings beat estimates in Q1 while revenues slightly missed the same. The company’s lead candidate EDIT-101 along with CRISPR gene editing to treat LCA10, a genetic illness that causes blindness, is being developed in partnership with Allergan. The disease has significant unmet need as no therapies are yet approved. A study on EDIT-101 initiated patient dosing in March 2020. If successfully developed, the candidate will boost growth prospects of the company. Editas has collaborations with big companies for its CRISPR technology, which provide research support and funds to pursue pipeline development. It is developing EDIT-301 for SCD and beta-thalassemia. However, due to lack of a marketed product, it is heavily dependent on its partners for revenues, which is a woe. Shares have underperformed the industry year to date." (6/1/2020)
  • 2. Chardan Capital analysts commented, "We anticipate better visibility around potential timing of data readouts as dosing gets underway. Below, we highlight thoughts on what we know of the program thus far." (7/25/2019)

Has Editas Medicine been receiving favorable news coverage?

Press coverage about EDIT stock has trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Editas Medicine earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Editas Medicine.

Who are some of Editas Medicine's key competitors?

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Micron Technology (MU), Alibaba Group (BABA), Square (SQ), Advanced Micro Devices (AMD), Shopify (SHOP), Intel (INTC) and Canopy Growth (CGC).

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the following people:
  • Dr. Charles Albright, Chief Scientific Officer (Age 61)
  • Ms. Cynthia L. Collins, Interim CEO & Director (Age 61)
  • Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
  • Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 65)
  • Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member

When did Editas Medicine IPO?

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $33.14.

How big of a company is Editas Medicine?

Editas Medicine has a market capitalization of $1.83 billion and generates $20.53 million in revenue each year. The company earns $-133,750,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Editas Medicine employs 133 workers across the globe.

What is Editas Medicine's official website?

The official website for Editas Medicine is www.editasmedicine.com.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.